The Danish pharmaceutical giant Novo Nordisk has announced it will invest 1.5 billion kroner in a new haemophilia treatment manufacturing facility in Kalundborg.
The new 7,500 sqm facility will create an estimated 100 new jobs in Kalundborg, where Novo Nordisk already employs more than 2,800 people.
“The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark,” explained Henrik Wulff, the executive vice president of the product supply division at Novo Nordisk.
bbabo.Net